10-Q 1 v361425_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

Commission file number 0-13092

SPECTRASCIENCE, INC.

(Exact name of registrant

as specified in its charter)

Minnesota	41-1448837
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

11568 Sorrento Valley Rd., Suite 11

San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 847-0200

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES o NO x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such files). YES o NO x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o

Non-accelerated filer o	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ¨ NO x

The number of shares of the registrant’s common stock, par value $0.01 per share, outstanding on March 28, 2014 was 167,343,253.

SPECTRASCIENCE, INC.

FORM 10-Q

For the Three and Six Months Ended June 30, 2013

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION:

Item 1.	Financial Statements (Unaudited)	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26

Item 4.	Controls and Procedures	26

PART II	OTHER INFORMATION

Item 1.	Legal Proceedings	28

Item 1A.	Risk Factors	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 3.	Defaults Upon Senior Securities	28

Item 4.	Mine Safety Disclosures	29

Item 5.	Other Information	29

Item 6.	Exhibits	29

SIGNATURES		30

PART I FINANCIAL INFORMATION:

Item 1. Financial Statements

SpectraScience, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

	June 30,			December 31,
	2013			2012
	(Unaudited)			(Audited)

ASSETS
Current assets:
Cash and cash equivalents	$	5,394		$	90,192
Accounts receivable, net		120,000			-
Inventories		143,963			202,077
Deferred debt issuance costs		125,152			165,649
Prepaid expenses and other current assets		148,436			191,030
Total current assets		542,945			648,948

Fixed assets, net		48,777			85,592
Patents, net		1,596,063			1,678,787
	$	2,187,785		$	2,413,327

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	1,065,266		$	861,698
Convertible debt, net of discounts of $321,915 as of June 30, 2013 and
$520,851 as of December 31, 2012		1,477,028			608,622
Derivative liability		3,356,009			2,335,560
Accrued Expenses		374,909			183,855
Total current liabilities		6,273,212			3,989,735

COMMITMENTS

Stockholders' deficit
Series A Convertible Preferred Stock, $.01 par value;
0 shares authorized, issued and outstanding as of June 30, 2013 and
December 31, 2012		-			-
Series B Convertible Preferred Stock, $.01 par value;
2,585,000 shares authorized, issued and outstanding as of June 30, 2013 and
December 31, 2012; liquidation value of $517,000 plus accumulated and
and unpaid dividends of $106,931 as of June 30, 2013 and December 31, 2012		25,850			25,850
Series C Convertible Preferred Stock, $.01 par value;
1,000,000 shares authorized; 500,000 and 1,000,000 shares issued and
outstanding as of June 30, 2013 and December 31, 2012; liquidation value of
$100,000 and $200,000 as of June 30, 2013 and December 31, 2012		5,000			10,000
Common stock, $.01 par value;
321,415,000 shares authorized; 161,795,047 and 152,229,665 shares issued
and outstanding as of June 30, 2013 and December 31, 2012		1,617,950			1,522,297
Additional paid in capital		36,178,957			35,491,603
Accumulated deficit		(41,913,184	)		(38,626,158	)
Total stockholders' deficit		(4,085,427	)		(1,576,408	)
	$	2,187,785		$	2,413,327

See accompanying summary of accounting polices and notes to unaudited condensed consolidated financial statements.

SpectraScience, Inc. and Subsidiary

Condensed Consolidated Statements of Operation

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2013			2012			2013			2012

Revenue	$	120,000		$	310,125		$	120,000		$	310,125
Cost of revenue		73,513			200,294			73,513			200,294
Gross profit		46,487			109,831			46,487			109,831

Operating expenses:
Research and development		193,453			289,413			380,910			669,699
General and administrative		654,877			652,754			1,152,580			1,200,400
Sales and marketing		89,685			132,056			167,070			240,751
		938,015			1,074,223			1,700,560			2,110,850

Loss from operations		(891,528	)		(964,392	)		(1,654,073	)		(2,001,019	)

Other expense (income)
Interest expense		66,511			116,309			123,092			154,336
Change in fair value of derivative and
warrant liabilities		(1,032,821	)		2,889,557			83,198			4,471,963
Amortization of derivative and warrant
liabilities discount		556,297			1,094,437			1,020,365			1,445,862
Amortization of deferred debt issuance
costs and original issue discount		200,503			461,289			391,072			604,861
(Gain) loss on extinguishment of debt		(13,807	)		-			16,989			-
Other expense (income), net		(4,281	)		1,924			(1,763	)		1,868
		(227,598	)		4,563,516			1,632,953			6,678,890

Net loss	$	(663,930	)	$	(5,527,908	)	$	(3,287,026	)	$	(8,679,909	)

Basic and diluted loss per share	$	(0.00	)	$	(0.05	)	$	(0.02	)	$	(0.08	)

Weighted average common shares outstanding:
Basic and diluted		158,843,541			108,041,084			157,152,228			108,041,084

See accompanying summary of accounting polices and notes to unaudited condensed consolidated financial statements.

SpectraScience, Inc. and Subsidiary

Condensed Consolidated Statement of Shareholders' Deficit

For the six months ended June 30, 2013

(unaudited)

															Additional					Total
	Series B Preferred Stock				Series C Preferred Stock						Common Stock				Paid-In		Accumulated			Shareholders'
	Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			Deficit

Balance December 31, 2012		2,585,000	$	25,850		1,000,000		$	10,000			152,229,665	$	1,522,297	$	35,491,603	$	(38,626,158	)	$	(1,576,408	)

Non-cash issuance of stock options																199,429		-			199,429
Common stock issued for services		-		-		-			-			4,000,000		40,000		204,500		-			244,500
Warrants issued with convertible notes payable		-		-		-			-			-		-		19,944		-			19,944
Conversion of convertible notes payable		-		-		-			-			5,065,382		50,653		246,492		-			297,145
Conversion of Series C Convertible Preferred		-		-		(500,000	)		(5,000	)		500,000		5,000		-		-			-
Loss on debt extinguishment		-		-		-			-			-		-		16,989		-			16,989
Net loss		-		-		-			-			-		-		-		(3,287,026	)		(3,287,026	)

Balance June 30, 2013		2,585,000	$	25,850		500,000		$	5,000			161,795,047	$	1,617,950	$	36,178,957	$	(41,913,184	)	$	(4,085,427	)

SpectraScience, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended June 30,
	2013			2012
Operating activities:
Net loss	$	(3,287,026	)	$	(8,679,909	)
Adjustments to reconcile net loss
to cash used in operating activities:
Provision for uncollectable accounts receivable		4,281			-
Amortization and depreciation		119,539			189,864
Non-cash issuance of stock options		199,429			192,937
Amortization of derivative and warrant liabilities discount		1,020,365			1,445,862
Amortization of deferred debt issuance costs and original issue discount		391,072			604,861
Change in fair value of derivative and warrant liabilities		83,198			4,471,963
Loss on extinguishment of debt		16,989			-
Fair market value of common stock issued for services		244,500			-
Changes in assets and liabilities:
Accounts receivable		(124,281	)		(286,087	)
Inventory		58,114			25,458
Prepaid expense and other assets		42,594			12,914
Accounts payable		194,954			21,328
Accrued expenses		258,914			85,950
Net cash used in operating activities		(777,358	)		(1,914,859	)

Investing activities:
Purchases of fixed assets		-			(4,170	)
Net cash used in investing activities		-			(4,170	)

Financing activities:
Proceeds from issuance of convertible notes payable		862,000			2,233,000
Debt issuance costs		(169,440	)		(379,402	)
Net cash provided by financing activities		692,560			1,853,598

Net increase (decrease) in cash and cash equivalents		(84,798	)		(65,431	)

Cash and cash equivalents, beginning of year		90,192			250,723

Cash and cash equivalents, end of period	$	5,394		$	185,292

Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-
Non Cash Investing and Financing Activities:
Conversion of convertible notes to common stock	$	263,157		$	-
Conversion of interest due on convertible notes to common stock	$	33,988		$	-
Exchange of interest due on convertible notes to new notes	$	25,259		$	-
Conversion of preferred stock to common stock	$	5,000		$	-

See accompanying summary of accounting polices and notes to unaudited condensed consolidated financial statements.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements

1. Nature of Business and Basis of Presentation

Description of Business

SpectraScience, Inc. was incorporated in the State of Minnesota on May 4, 1983 as GV Medical, Inc. In October 1992, GV Medical discontinued its prior business, refocused its development efforts and changed its name to SpectraScience, Inc. The “Company,” hereinafter, refers to SpectraScience, Inc. and its wholly owned subsidiaries Luma Imaging Corporation (“LUMA”) and Spectra Science International, Inc. (“International”). Since 1996, the Company has focused primarily on developing the WavSTAT Optical Biopsy System (the “WavSTAT System”).

The Company has developed and received the European CE mark approval to market a proprietary, minimally invasive technology that optically illuminates tissue in real-time to distinguish between normal, pre-cancerous or cancerous cells without the need to remove the subject cell tissue from the body to make such determinations. The WavSTAT System operates by using cool, safe laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer, and if warranted, to begin immediate treatment during the same procedure. Beginning in December 2011, the WavSTAT 4 version of the product began to be sold in the European Union for colon cancer detection. In June 2012, the Company entered into a distribution agreement with PENTAX Europe, GmbH, for the sale of its systems internationally.

On November 6, 2007, the Company acquired the assets of LUMA in an equity transaction accounted for as an acquisition of assets and now operates LUMA as a wholly-owned subsidiary of the Company. LUMA had acquired the assets from a predecessor company that had developed, and received FDA approval for, a non-invasive diagnostic imaging system that can detect cervical cancer precursors and which utilizes an underlying technology that is similar to that of the WavSTAT System. The addition of the LUMA technology to the Company’s existing WavSTAT System technology provides the Company with a broad suite of fluorescence-based intellectual property and know-how. During the fiscal year ended December 31, 2010, the Company wrote off the remaining fair value of the LUMA inventory in order to focus on the continued development and marketing of the WavSTAT System. The Company retained the intellectual property of LUMA for use in the development of future generations of the WavSTAT System.

The transaction was accounted for as an acquisition of assets that included intellectual property, inventory and equipment. The intellectual property consisted of a total of 34 issued U.S. patents and 28 additional patent applications.

Basis of Presentation

The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the six month period ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. These statements should be read in conjunction with the financial statements and related notes, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

Going Concern

Historically, the Company’s sources of cash have come from the issuance and sales of equity securities and convertible debentures. The Company’s historical cash outflows have been primarily used for operating activities including research, development, administrative and sales activities. Fluctuations in the Company’s working capital due to timing differences of its cash receipts and cash disbursements also impact its cash flow. The Company expects to incur significant additional operating losses through at least the end of 2013, as it completes proof-of-concept trials, conducts outcome-based clinical studies and increases sales and marketing efforts to commercialize the WavSTAT4 Systems in Europe. If the Company does not receive sufficient funding, there is substantial doubt that the Company will be able to continue as a going concern. The Company may incur unknown expenses or may not be able to meet its revenue forecast, and one or more of these circumstances would require the Company to seek additional capital. The Company may not be able to obtain equity capital or debt funding on terms that are acceptable. Even if the Company receives additional funding, such proceeds may not be sufficient to allow the Company to sustain operations until it becomes profitable and begins to generate positive cash flows from operations.

As of June 30, 2013, the Company had a working capital deficit of $5,730,267 and cash and cash equivalents of $5,394, compared to a working capital deficit of $3,340,787 and cash and cash equivalents of $90,192 as of December 31, 2012. In December 2011, the Company entered into an Engagement Agreement with Laidlaw & Company (UK) Ltd., which Engagement Agreement was amended in July 2012. Under the Engagement Agreement, Laidlaw agreed to assist the Company in raising up to $20.0 million in capital over a two year period from the date of the Engagement Agreement. During the six months ended June 30, 2013, the Company raised $692,560, net of transaction costs, under this agreement. Subsequent to June 30, 2013, the Company has engaged another agent to assist the Company with raising capital and has commenced raising capital on its own. However, if the Company does not receive additional funds in a timely manner, the Company could be in jeopardy as a going concern. The Company may not be able to find alternative capital or raise capital or debt on terms that are acceptable. Management believes that if the events defined in the Engagement Agreement occur as expected, or if the Company is otherwise able to raise a similar level of funds, such proceeds will be sufficient to allow the Company to sustain operations until it attains profitability and positive cash flows from operations. However, the Company may incur unknown expenses or may not be able to meet its revenue expectations requiring it to seek additional capital. In such event, the Company may not be able to find capital or raise capital or debt on terms that are acceptable.

The holders of Convertible Debentures control the conversion of the Convertible Debentures and certain of the Convertible Debentures were not converted at their maturity constituting a potential default on the matured, but unconverted, Convertible Debentures. The holders of these unconverted Convertible Debentures have the option to declare their Convertible Debentures in default. In the event of such default, principal, accrued interest and other related costs are immediately due and payable in cash. As of June 30, 2013, Convertible Debentures with a face value of $566,319 held by 15 individual investors are in default. None of these investors have served notice of default on the Convertible Debentures held by them.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

2. Summary of Significant Accounting Policies

Revenue recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of the Company’s products is generally recognized when title and risk of loss transfers to the customer, the terms of which are generally free on board shipping point. The Company uses customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the price is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer.

Consolidation

The accompanying consolidated financial statements include the accounts of SpectraScience, Inc. and its wholly-owned subsidiaries LUMA, and International. All significant intercompany balances and transactions have been eliminated in consolidation.

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company's operations are subject to significant risk and uncertainties, including financial, operational, technological, regulatory and other risks associated with a short history of product sales, including the potential risk of business failure.

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Significant estimates made by management include, among others, realization of long-lived assets including intangible assets, assumptions used to value stock options, assumptions used to value the common stock issued and assumptions related to the determination of the fair value of the derivative components associated with the Company’s Convertible Debentures. Actual results could differ from those estimates.

Inventory Valuation

The Company states its inventories at the lower of cost or market value, determined on a specific cost basis. The Company provides inventory allowances when conditions indicate that the selling price could be less than cost due to obsolescence and reductions in estimated future demand. The Company balances the need to maintain strategic inventory levels with the risk of obsolescence due to changing technology and customer demand levels. Unfavorable changes in market conditions may result in a need for additional inventory reserves that could adversely impact the Company’s gross margins. Conversely, favorable changes in demand could result in higher gross margins when the Company sells products.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

Valuation of Long-lived Assets

The Company’s long-lived assets consist of property and equipment and intangible assets. Equipment is carried at cost and is depreciated over the estimated useful lives of the assets, which are generally two to three years, and leasehold improvements are amortized over the lesser of the lease term or the estimated useful lives of the improvements. The straight-line method is used for depreciation and amortization. Intangible assets consist of patents, which are amortized using the straight-line method over the estimated useful lives of the patents. The Company does not capitalize external legal costs and filing fees associated with obtaining patents on its new discoveries. Acquired intellectual property is recorded at cost and is amortized over its estimated useful life. The Company believes the useful lives assigned to these assets are reasonable. The Company assesses the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in management’s estimate of future cash flows to determine recoverability of these assets. If management’s assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.

Stock-Based Compensation

The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company adopted ASC 718 on January 1, 2006. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option-pricing model (the “Black-Scholes Model”). The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises its estimate in subsequent periods if actual forfeitures differ from those estimates.

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to employees and non-employees as the consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options at the end of each reporting period.

As of June 30, 2013, the Company had one stock-based employee compensation plan under which it makes grants, the 2011 Equity Incentive Plan (the “EIP”). The EIP provides for the grant of incentive stock options (“ISOs”), nonqualified stock options (“NQSOs”) and restricted stock awards to full-time employees (who may also be directors) and NQSOs and restricted stock awards to non-employee directors, consultants, customers, vendors or providers of services. The exercise price of any ISO may not be less than the fair market value of the common stock on the date of grant and the term shall not exceed ten years. The amount reserved under the 2011 EIP is 15,000,000 shares of common stock. At June 30, 2013, the Company had outstanding 19,491,667 options under the EIP and the Company’s prior Amended 2001 Stock Plan representing approximately 12% of the Company’s outstanding shares (10,913,542 of which were exercisable), with 6,453,333 available for future issuance under the 2011 EIP. Awards under the Company’s EIP generally vest over four years.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

The fair value of options granted were estimated at the date of grant using a Black-Scholes Model which includes several variables including expected life, risk free interest rate, expected stock price volatility, stock option exercise patterns and expected dividend yield. The Company also must estimate forfeitures for employee stock options. These models and assumptions are complex and may change future expenses by increasing or decreasing stock-based compensation expense. There were no stock options granted during the three and six month periods ended June 30, 2013. Management used the following weighted average assumptions to value stock options granted during the three and six month periods ended June 30, 2013 and 2012:

	Three months ended June 30,		Six months ended June 30,
	2013	2012	2013	2012

Expected term of options	None	None	None	5 years
Exercise price
Expected volatility	None	None	None	114%
Expected dividends	None	None	None	None
Risk-free interest rate	None	None	None	0.85%
Forteitures	None	None	None	None

Management believes estimated forfeitures for employee stock options granted under the EIP would have a negligible effect on expenses because such forfeitures would be a very small percentage. Stock option grants have been to a group of individuals that have a high desire to see the Company succeed and have aligned themselves to that end.

The expected lives used in the calculations were selected by management based on past experience, forward looking profit forecasts and estimates of what the trading price of the Company’s stock might be at different future dates.

The risk-free interest rates used in the calculations are the five-year U.S. Treasury rates as published on the date of the applicable stock option grant.

Volatility is a calculation based on fluctuations in the Company’s stock price over a historical time period consistent with the estimated life of the option.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

Options outstanding as of June 30, 2013 are as follows:

			Outstanding Options

	Options				Weighted Average		Weighted Average		Aggregate
	Available for		Plan Options		Exercise Price		Remaining Contractual		Intrinsic
	Grant		Outstanding		Per Share		Term (years)		Value (1)
Outstanding at January 1, 2013		6,453,333		19,491,667	$	0.18		8.20	$	-
Granted		-		-	$	-		-	$	-
Cancelled		-		-	$	-		-	$	-
Exercised		-		-	$	-		-	$	-
Outstanding at June 30, 2013		6,453,333		19,491,667	$	0.18		7.32	$	-

Exercisable at June 30, 2013				10,913,542	$	0.22		6.39	$	-

Weighted average fair value of options
granted during the period				-	$	-		-	$	-

(1) These amounts represent the excess, if any, between the exercise price and $0.05, the closing market price of the Company’s common stock on June 30, 2013 as quoted on the Over-the-Counter Bulletin Board under the symbol “SCIE”.

There were no options exercised during the three and six month periods ended June 30, 2013 and 2012. At June 30, 2013, total unrecognized estimated employee compensation cost related to non-vested stock options granted prior to that date is $643,135, which we expect to be recognized over the next four years.

Earnings (Loss) Per Share

Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Common equivalent shares are excluded from the computation if their effect is anti-dilutive.

For the periods ended June 30, 2013 and 2012, the following common equivalent shares were evaluated to determine if their inclusion in the calculation of loss per share was dilutive.

	June 30,		June 30,
	2013		2012

Preferred Stock		3,085,000		3,585,000
Convertible debentures		27,231,569		41,021,402
Options		19,491,667		16,295,000
Warrants		71,185,727		53,396,441
Total		117,908,963		110,712,843

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

The following table sets forth the computation of basic and diluted loss per share and incorporates income and expense related to convertible debentures and warrants and a change in shares that could be outstanding on the conversion of the convertible debentures for the three and six month periods ended June 30, 2013 and 2012:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2013			2012			2013			2012

Numerator:
Net income (loss) for basic earnings per share	$	(663,930	)	$	(5,527,908	)	$	(3,287,026	)	$	(8,679,909	)
Additions:
Interest expense related to convertible debentures		19,941			-			2,425
Amortization of deferred debt costs and original
issue discount		9,391			-			-
Discounts on warrants and derivative debt		67,738			-
Subtractions:
Gain (loss) on debt extinguishment		(13,807	)		-			30,796
Change in fair value of derivative securites		(461,596	)		-			(109,005	)
Net loss for diluted earnings per share	$	(1,042,263	)	$	(5,527,908	)	$	(3,362,810	)	$	(8,679,909	)

Denominator:
Weighted average basic shares outstanding		158,843,541			108,041,084			157,152,228			108,041,084
Additions:
Assumed conversion of convertible debentures
at beginning of period		9,838,907			-			2,204,467			-
Assumed conversion of exchanged convertible
debentures during the period		230,414			-			-			-
Subtractions:
Convertible debentures converted during the period		(936,214	)		-			(1,822,035	)		-
Potentially dilutive common shares		9,133,107			-			382,432			-

Denoninator for diluted earnings per share-
Adjusted weighted average shares		167,976,648			108,041,084			157,534,660			108,041,084

Income (loss) per share
Basic	$	(0.00	)	$	(0.05	)	$	(0.02	)	$	(0.08	)
Diluted	$	(0.01	)	$	(0.05	)	$	(0.02	)	$	(0.08	)

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

Inventories

Inventories consisted of the following at June 30, 2013 and December 31, 2012:

	June 30,			December 31,
	2013			2012

Raw materials	$	124,905		$	124,905
Finished goods		66,652			124,766
		191,557			249,671
Reserve for obsolescence		(47,594	)		(47,594	)
	$	143,963		$	202,077

3. Liabilities

Convertible Debentures

As of June 30, 2013, the Company has issued and outstanding Convertible Debentures (“Debentures”) with original terms of six months, an interest rate ranging from 16-20% per year and an original issue discount of 5% which, at the option of the holder, may convert into common stock at an initial conversion price ranging from $0.0573 to $0.099 per share. The Debentures were issued with detachable five year cashless Holders Warrants that allow the holders to purchase one share of stock for each two shares available under the converted Debentures at an exercise price ranging from $0.0745 to $0.1287 per share. In addition, the Company issued five year cashless Agent Warrants equal to 10% of the total number of shares issuable under the Debentures and Holders Warrants at an exercise price ranging from $0.0745 to $0.1287 per share. For Debentures issued previous to March 31, 2013, at the option of the Debenture holder, the terms of the Debentures and Holders Warrants are subject to an exchange feature in the event that the Company issues securities with terms more favorable than those of the then outstanding Debentures and Holders Warrants. Debentures issued subsequent to March 31, 2013 do not contain such an exchange clause.

As of June 30, 2013 and December 31, 2012, the balances of the Debentures are as follows:

	June 30,			December 31,
	2013			2012

Balance at beginning of period	$	1,129,473		$	-
Issuance of debentures for cash		862,000			3,186,000
Original issue discount		45,369			167,685
Debentures surrended in exchange transaction		(300,002	)		-
Debentures issued in exchange transaction		325,261			-
Debentures converted to common stock		(263,158	)		(2,224,212	)
Convertible debt		1,798,943			1,129,473
Less unamortized costs of financing		321,915			520,851
Convertible debt, net of unamortized costs	$	1,477,028		$	608,622

Convertible debt in default	$	566,319		$	-

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

Derivative Liability

Since the Company issued Convertible Debentures which included Holders Warrants, Agent Warrants and a conversion option that includes a possible exchange feature in the event of a future financing on terms more favorable than those of the existing warrants and debentures, this results

in the warrants and conversion feature of the debentures being recorded as a liability and measured at fair value. The Company measures these warrants and conversion feature using a combination of Black-Scholes option valuation models and Binomial Lattice option valuation models using similar assumptions to those described under “Stock-Based Compensation.” The time period over which the Company will be required to evaluate the fair value of the warrants is approximately five years and the time period over which the Company will be required to evaluate the fair value of the conversion feature is the lesser of six months or conversion.

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment of the probability of a more favorably priced future financing or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Debentures, which the convertible feature is associated with, mature. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

As of June 30, 2013 and December 31, 2012, the balances of the Derivative Liability are as follows:

				Conversion
	Warrants			Feature			Total

Balance at January 1, 2012	$	-		$	-		$	-
Liabililty on issuance of debt and warrants		2,510,919			2,167,341			4,678,260
Change in fair value at year end		(780,875	)		991,912			211,037
Elimination of liability on conversion		-			(2,553,737	)		(2,553,737	)
Balance at December 31, 2012		1,730,044			605,516			2,335,560

Liabililty on issuance of debt and warrants		762,105			929,156			1,691,261
Change in fair value at period end		(237,313	)		(396,905	)		(634,218	)
Elimination of liability on conversion		-			(36,594	)		(36,594	)
Derivative liability	$	2,254,836		$	1,101,173		$	3,356,009

Debentures issued subsequent to March 31, 2013 did not contain an exchange provision and were accounted for using the equity method of valuing the note and warrant. For the three and six months ended June 30, 2013, $33,182 was recorded as additional paid in capital.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

4. Shareholders’ Equity

Common Stock

In January 2013, the Company issued 3,000,000 shares of restricted common stock to two vendors for services. The fair value of the vested portion of these shares was determined to be $194,500. In June 2013, the Company issued 1,000,000 shares of restricted common stock to one vendor for services. The fair value of the vested portion of these shares was determined to be $50,000.

During the six months ended June 30, 2013, holders of Convertible Debentures with a face value of $263,158 converted their debentures into 4,592,636 shares of restricted common stock. In addition, associated with these debentures, the Company paid $33,988 in accrued interest by issuing 472,746 shares of restricted common stock.

In April 2013, a shareholder converted 500,000 shares of Series C Convertible Preferred stock into 500,000 shares of restricted common stock.

Warrants

During the six months ended June 30, 2013, in conjunction with the sale of Convertible Debentures, the Company issued five year common stock purchase warrants to acquire 10,293,052 shares to holders of the Debentures and as compensation to Agents. These warrants have exercise prices ranging from $0.0745 to $0.1287 per share.

In addition, during the six months ended June 30, 2013, the holders of common stock purchase warrants to acquire 2,206,273 shares at an exercise price of $0.1287 exchanged their warrants for new warrants to acquire 4,031,956 shares at an exercise price of $0.0745 under the exchange provisions of their Convertible Debentures.

The balance of all warrants outstanding as of June 30, 2013 is as follows:

				Weighted
				Average
				Exercise
Warrants	Shares			Price
Outstanding at January 1, 2013		59,066,992		$	0.18
Granted		10,293,052		$	0.07
Exchanged cancelled		(2,206,273	)	$	0.13
Exchanged issued		4,031,956		$	0.08
Cancelled		-		$	-
Exercised		-		$	-
Outstanding at June 30, 2013		71,185,727		$	0.16

Exercisable at end of the the period		71,185,727		$	0.16

5. Fair Value Measurements

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

The Company's balance sheet contains derivative and warrant liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: uses unobservable inputs that are not corroborated by market data.

The fair value of the Company’s recorded derivative and warrant liabilities is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A modified Binomial Lattice option valuation model was used to determine the fair value with similar assumptions to those described under “Stock-Based Compensation”. The Company records derivative and warrant liabilities on the consolidated balance sheets at fair value with changes in fair value recorded in the consolidated statements of operations.

The following table presents the balances of liabilities measured at fair value on a recurring basis by level as of June 30, 2013:

	Fair Value Measurements Using
	Quoted Prices in		Significant Other		Significant
	Active Markets for		Observable		Unobservable
	Identical Assets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total

As of June 30, 2013
Derivative liability	$	-	$	-	$	1,101,173	$	1,101,173
Warrant liability		-		-		2,254,836		2,254,836
Total	$	-	$	-	$	3,356,009	$	3,356,009

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the six months ended June 30, 2013:

	Warrant			Derivative			Total
	Liability			Liability			Liability
Balance Deember 31, 2012	$	1,730,044		$	605,516		$	2,335,560

Liability on issuance of debt and warrants		762,105			929,156			1,691,261

Change in estimated fair value (1)		(237,313	)		(396,905	)		(634,218	)

Elimination of liability on conversion		-			(36,594	)		(36,594	)

Balance June 30, 2013	$	2,254,836		$	1,101,173		$	3,356,009

(1) Included in the Statement of Operations on the line “Change in fair value of derivative liabilities.”

Management used the following inputs to value the Derivative and Warrant Liabilities for the six months ended June 30, 2013:

	Derivative Liability	Warrant Liability
Expected term	6 months	5 years
Exercise price	$0.0573 - $0.099	$0.075 - $0.1287
Expected volatility	191% - 201%	173% - 176%
Expected dividends	None	None
Risk-free interest rate	.10% - .14%	.77% - 1.41%
Forteitures	None	None

In computing the fair value of the derivative and warrant liability at June 30, 2013 for instruments under the Binomial Lattice option-pricing model, management assumed a 75% probability of a down round financing event at an assumed stock price of $0.030 and a 50% to 90% probability of note holders exchanging their existing notes.

6. Contingencies

None

7. Subsequent Events

Note Payable to an Affiliate

In September 2013, the Company issued a nine month unsecured note with a face value of $45,000 and 500,000 restricted shares of common stock to an affiliate of the Company in exchange for $54,325 in cash. The imputed annual rate of interest was calculated to be 18.4% and is to be repaid in nine equal monthly installments.

Convertible Debentures and Warrants

From July through March 2014, the Company sold $1,701,113 of 5% Original Issue Discount Unsecured Convertible Debentures (the “Debentures”) to accredited investors for aggregate consideration of $1,616,376. The Debentures mature in six to twelve months, carry a fixed conversion price ranging from $.045 to $0.0573 per share, an annual interest rate ranging from 10% to 16% and are convertible into 37,752,273 shares of common stock at maturity. The Company received net cash proceeds of approximately $1,488,000 after payment of fees and expenses of approximately $128,000. In addition, the Company issued the holders of the Debentures detachable five-year warrants to purchase 18,876,136 additional shares of common stock and issued to the placement agent of the offering warrants to purchase 504,716 shares of common stock all at an exercise price ranging from $0.0745 to $0.090 per share.

SpectraScience, Inc.

Notes to Unaudited Condensed Financial Statements (continued)

In November 2013, the holders of Convertible Debentures with an aggregate face value of $264,211, interest rate of 16% and conversion prices ranging from $0.0573 to $0.099 per share exchanged their debentures for new debentures with a conversion price of $0.045 per share and an interest rate of 10%. In addition, associated with these new Convertible Debentures, the Company increased the face value by $36,895, which was the accrued interest at the time of exchange, to $301,106. The maturity date for the new debentures is November 30, 2014. In addition, the Company issued new five-year warrants to purchase 3,145,662 shares of common stock with an exercise price of $0.09 per share in exchange for warrants to purchase 1,660,948 shares of common stock with exercise prices ranging from $0.0745 to $0.1287 per share.

Common Stock

In November 2013, a holder of a Convertible Debenture with a face value of $210,526 converted his Convertible Debenture into 3,674,101 shares of restricted common stock. In addition, associated with this Convertible Debenture, the Company paid $25,378 in accrued interest by issuing 442,905 shares of common stock.

In February 2014, an affiliate of the Company exercised a portion of his stock options into 931,200 shares of restricted common stock at an exercise price of $0.02 for proceeds to the Company of $18,624.

Subsequent events have been evaluated through the date financial statements are filed with the Securities and Exchange Commission.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q (the “Report”) contains forward-looking statements that are not related to historical results, including, without limitation, statements regarding our business strategy and objectives, our anticipated duration of periods of net loss, our near term operating goals, our expectations regarding the market for our products, the introduction of our products in new international markets and our beliefs with respect to opportunities and industry conditions in those markets, our beliefs about our products, product development, acquisition or licensing of complementary technologies and expectations with respect to our products’ performance and acceptance, the effect on expenses of pursuing the introduction of our product in Europe, the results of and our intentions with respect to our distribution agreement with PENTAX Europe GmbH, our beliefs about the strengths of and our intent regarding our intellectual property portfolio, our regulatory goals and developments, anticipated clinical trials and research, our ability to raise capital outside of our agreement with Laidlaw, our agreement with Laidlaw and its effect on our future capital resources and future financial position, our expectations with respect to stock option expense recognition, our future cash needs, the sufficiency of our working capital, the effect on our financial position of the evaluation of our derivative liabilities, and our operating losses for the remainder of the current fiscal year. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, there can be no assurance that such assumptions will prove to be accurate and actual results could differ materially from those discussed in the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause or contribute to such differences, including, but not limited to, changes in law or regulatory policies, unanticipated competition from other similar businesses, adverse outcomes from litigation, unexpected employee departures or disruptions, adverse market and general economic factors and other factors described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. Such forward-looking statements are qualified in their entirety by the cautions and risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Business

SpectraScience, Inc. (the “Company,” “SpectraScience,” “we,” “our,” or “us”) develops and manufactures innovative Laser Induced Fluorescence spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without removing tissue from the body. The WavSTAT Optical Biopsy System (the “WavSTAT System”) is SpectraScience's first product to incorporate its proprietary fluorescence technology for clinical use. The WavSTAT System carries the CE mark designation which allows for the sale and marketing in the European Union for the diagnosis of cancer. We are developing light-based diagnostics for additional indications including inflammatory bowel disease and esophageal cancer. Once these additional applications are developed we plan to self-certify for CE mark approval for sale in the European Union and then file an application with the FDA seeking permission to begin marketing for that indication for use in the United States. We believe we have a strong intellectual property portfolio that will allow us to continue to expand its WavSTAT cancer diagnosis platform to address the diagnosis of multiple cancers, utilize additional proprietary bio-photonic techniques to improve the WavSTAT’s overall diagnostic performance and ultimately allow for the detection of cancer and pre-cancer over a relatively large area of examined tissue.

Our principal executive offices are located at 11568 Sorrento Valley Rd., Suite 11, San Diego, CA 92121. We can be reached by telephone at (858) 847-0200; by fax at (858) 847-0880; or by email at info@spectrascience.com. We have a Web site at http://www.spectrascience.com. The information contained on our Web site shall not be deemed to be a part of this Report.

Plan of Operation

During the three and six month periods ended June 30, 2013, SpectraScience carried forward on the improvements made to the WavSTAT4 in fiscal 2011 and continued working with PENTAX Europe, GmbH (“PENTAX”), for distribution of its products in Europe the Middle East and Africa.

Over the next 12 months, SpectraScience intends to:

Market and sell the WavSTAT4 Optical Biopsy System colon cancer diagnostic application through PENTAX in the European Union;

Conduct country-specific evaluation trials to demonstrate the effectiveness and cost benefit of the WavSTAT4 Optical Biopsy System in each relevant European jurisdiction;

Coordinate the creation and publication of scientific papers and presentations related to the country-specific evaluation trials to support widespread education and adoption of the WavSTAT4 ;

Pursue the introduction of the WavSTAT4 colon cancer application in other international markets, in particular Russia and India;

Begin meeting with the FDA towards the preparation and submission of a Supplemental PMA filing with the FDA for the WavSTAT4 and plan for additional clinical trials to support eventual approval for sale in the United States;

Begin the design and planning for the next generation of multi-modal fluorescence and broadband spectroscopy systems at our facility in San Diego, California; and

Continue to expand and refine our intellectual property portfolio through acquisition of complimentary technology.

Results of Operations

Comparison of the Three Months Ended June 30, 2013 and 2012

	Three Months Ended June 30,						Favorable
	2013			2012			(Unfavorable)			%

Revenue	$	120,000		$	310,125		$	(190,125	)		-61.3	%
Cost of revenue		73,513			200,294			126,781			63.3	%
Gross profit		46,487			109,831			(63,344	)		-57.7	%

Operating expenses:
Research and development		193,453			289,413			95,960			33.2	%
General and administrative		654,877			652,754			(2,123	)		-0.3	%
Sales and marketing		89,685			132,056			42,371			32.1	%
		938,015			1,074,223			136,208			12.7	%

Loss from operations		(891,528	)		(964,392	)		72,864			-7.6	%

Other expense (income)		(227,598	)		4,563,516			4,791,114			NM

Net income (loss)	$	(663,930	)	$	(5,527,908	)	$	4,863,978			-88.0	%

Revenues

Revenues for the quarter ended June 30, 2013 decreased $190,125, or 61.3%, to $120,000 compared to $310,125 for the quarter ended June 30, 2012. The primary reason for the revenue decrease was a decrease in the number of WaveSTAT4 Systems shipped, 4 in 2013 versus 8 in 2012 coupled with accessories shipped in 2012 of approximately $70,000 versus no shipments of accessories in 2013. We anticipate that revenue will increase as a result of our distribution agreement with PENTAX.

Cost of Revenue

Cost of revenue for the quarter ended June 30, 2013 decreased $126,781, or 63.3%, to $73,513 compared to $200,294 for the quarter ended June 30, 2012. The primary reason for the cost of revenue decrease was the reduction in revenue discussed above.

Research and Development Expenses

Research and development expenses decreased by $95,960, or 33.2%, to $193,453 for the quarter ended June 30, 2013 from $289,413 for the quarter ended June 30, 2012. This decrease was primarily due to a reduction in engineering development costs of approximately $85,000 and a reduction in payroll costs of approximately $27,000 offset by an increase in clinical expenses of approximately $5,000 and an increase in regulatory affairs costs of approximately $12,000. We anticipate that development costs will remain low but that clinical costs will increase as we proceed with our introduction of the WaveSTAT4 in Europe.

General and Administrative Expenses

General and administrative expenses increased by $2,123, or 0.3%, to $654,877 for the quarter ended June 30, 2013 from $652,754 for the quarter ended June 30, 2012. We anticipate that general and administrative expenses will increase as we increase our activity in Europe.

Sales and Marketing Expenses

Sales and marketing expenses decreased by $42,371, or 32.1%, to $89,685 for the quarter ended June 30, 2013 from $132,056 for the quarter ended June 30, 2012. The primary reason for the decrease was a decrease in payroll costs of approximately $6,000, a decrease in consulting costs of approximately $23,000 and a reduction in trade show and related costs of approximately $7,000. We anticipate that sales and marketing expenses will increase as we increase our activity in Europe.

Other Expense (Income)

Other expense (income) for the quarter ended June 30, 2013 was income of $227,598 compared to expense of $4,563,516 for the quarter ended June 30, 2012. This change was due primarily to the change in valuation of our derivative liabilities. We anticipate continued large fluctuations in other expense (income) as a result of quarterly re-evaluating these obligations.

Comparison of the Six Months Ended June 30, 2013 and 2012

	Six Months Ended June 30,						Favorable
	2013			2012			(Unfavorable)			%

Revenue	$	120,000		$	310,125		$	(190,125	)		-61.3	%
Cost of revenue		73,513			200,294			126,781			63.3	%
Gross profit		46,487			109,831			(63,344	)		-57.7	%

Operating expenses:
Research and development		380,910			669,699			288,789			43.1	%
General and administrative		1,152,580			1,200,400			47,820			4.0	%
Sales and marketing		167,070			240,751			73,681			30.6	%
		1,700,560			2,110,850			410,290			19.4	%

Loss from operations		(1,654,073	)		(2,001,019	)		346,946			-17.3	%

Other expense (income)		1,632,953			6,678,890			5,045,937			-75.6	%

Net loss	$	(3,287,026	)	$	(8,679,909	)	$	5,392,883			-62.1	%

Revenues

Revenues for the six months ended June 30, 2013 decreased $190,125, or 61.3%, to $120,000 compared to $310,125 for the six months ended June 30, 2012. The primary reason for the revenue decrease was a decrease in the number of WaveSTAT4 Systems shipped, 4 in 2013 versus 8 in 2012 coupled with accessories shipped in 2012 of approximately $70,000 versus no shipments of accessories in 2013. We anticipate that revenue will increase as a result of our distribution agreement with PENTAX.

Cost of Revenue

Cost of revenue for the six months ended June 30, 2013 decreased $126,781, or 63.3%, to $73,513 compared to $200,294 for the six months ended June 30, 2012. The primary reason for the cost of revenue decrease was the reduction in revenue discussed above.

Research and Development Expenses

Research and development expenses decreased by $288,789, or 43.1%, to $380,910 for the six months ended June 30, 2013 from $669,699 for the six months ended June 30, 2012. This decrease was primarily due to a reduction in engineering development costs of approximately $220,000 and a reduction in clinical studies expenses of approximately $58,000. We anticipate that development costs will remain low but that clinical costs will increase as we proceed with our introduction of the WaveSTAT4 in Europe.

General and Administrative Expenses

General and administrative expenses decreased by $47,820, or 4.0%, to $1,152,580 for the six months ended June 30, 2013 from $1,200,400 for the six months ended June 30, 2012. The primary reason for the decrease was a decrease in investor relations costs of approximately $54,000. We anticipate that general and administrative expenses will increase as we increase our activity in Europe.

Sales and Marketing Expenses

Sales and marketing expenses decreased by $73,681, or 30.6%, to $167,070 for the six months ended June 30, 2013 from $240,751 for the six months ended June 30, 2012. The primary reason for the decrease was a decrease in payroll costs of approximately $15,000, a decrease in consulting costs of approximately $22,000 and a reduction in trade show and related costs of approximately $36,000. We anticipate that sales and marketing expenses will increase as we increase our activity in Europe.

Other Expense (Income)

Other expense (income) for the six months ended June 30, 2013 was expense of $1,632,953 compared to expense of $6,678,890 for the six months ended June 30, 2012. This change was due primarily to the change in valuation of our derivative liabilities. We anticipate continued large fluctuations in other expense (income) as a result of quarterly re-evaluating these obligations.

Liquidity and Capital Resources

	As of						Increase
	June 30, 2013			December 31, 2012			(Decrease)
Working Capital

Current assets	$	542,945		$	648,948		$	(106,003	)
Current liabilities		6,273,212			3,989,735			2,283,477
Working capital deficit	$	(5,730,267	)	$	(3,340,787	)	$	2,389,480

Long-term debt	$	-		$	-		$	-

Stockholders' deficit	$	(4,085,427	)	$	(1,576,408	)	$	2,509,019

	Six Months Ended June 30,						Increase
	2013			2012			(Decrease)
Statements of Cash Flows Select Information

Net cash provided (used) by:
Operating activities	$	(777,358	)	$	(1,914,859	)	$	(1,137,501	)
Investing activities	$	-		$	(4,170	)	$	(4,170	)
Financing activities	$	692,560		$	1,853,598		$	(1,161,038	)

	As of				Increase
	June 30, 2013		December 31, 2012		(Decrease)
Balance Sheet Select Information

Cash and cash equivalents	$	5,394	$	90,192	$	(84,798	)

Accounts receivable	$	120,000	$	-	$	120,000

Inventories	$	143,963	$	202,077	$	(58,114	)

Accounts payable and accrued expenses	$	1,440,175	$	792,477	$	647,698

Since December 31, 2012, our net working capital deficit has increased from $3,340,787 to $5,730,267. The primary cause of this increase in the deficit is a result of the accounting treatment required for the Convertible Debentures and warrants issued over the past twelve months. We have paid principal and interest on the Convertible Debentures that have converted by issuing shares of common stock. At June 30, 2013, adjusting for the non-cash effect of the Convertible Debentures on our net working capital deficit, the adjusted net working capital deficit would have been approximately $2,374,000. We paid principal and interest owing on Convertible Debentures that have been converted by issuing shares of common stock. The holders of Convertible Debentures control the conversion of the Convertible Debentures and certain of the Convertible Debentures were not converted at their maturity constituting a potential default on these remaining matured, but unconverted, Convertible Debentures. The holders of these unconverted Convertible Debentures have the option to declare their Convertible Debentures in default. In the event of such default, principal, accrued interest and other related costs are immediately due and payable in cash.

During the six months ended June 30, 2013, Convertible Debentures with a face value of approximately $566,319 held by fifteen individual investors matured. These remain outstanding, but none of these fifteen investors have served notice of default on the Convertible Debentures held by them.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Report (the “Evaluation Date”). Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the Evaluation Date.

Changes in Internal Financial Controls

There was no change in the Company’s internal control over financial reporting that occurred during the Company’s most recently completed quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1.

Legal Proceedings

None

Item 1A.

Risk Factors

There have been no material changes in our risk factors from those disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended June 30, 2013 we issued the following equity securities:

		Number of			Amount of Debt
	Date of	Common Shares		Source of	Interest and
Common Stock	Issuance	Issued		Payment	Services
	5/24/2013		794,914	Conversion of Convertible Debt plus interest	$	45,549
	5/24/2013		803,731	Conversion of Convertible Debt plus interest	$	46,054
	6/5/2013		1,041,822	Conversion of Convertible Debt plus interest	$	59,696
	6/12/2013		1,000,000	Services	$	52,500
	6/20/2013		500,000	Conversion of 500,000 shares of Preferred Stock		-

Common Stock Purchase Warrants	Date of	Number of
Issued with Convertible Debentures	Issuance	Warrant Shares		Exercise Price		Expiraton Date
	4/25/2013		101,647	$	0.0745	4/25/2018
	4/30/2013		501,248	$	0.0745	4/30/2018
	6/6/2013		512,338	$	0.0745	6/6/2018
	6/14/2013		229,634	$	0.0745	6/14/2018
	6/14/2013		229,634	$	0.0745	6/14/2018
	6/20/2013		259,843	$	0.0745	6/20/2018
	6/30/2013		137,780	$	0.0745	6/30/2018

With respect to the above equity securities issuances, the Company relied on exemptions provided by Section 4(a)(2) and 3(a)9 of the Securities Act of 1933, as amended (the “Securities Act”). No advertising or general solicitation was employed in offering the securities. The securities were issued to a limited number of persons all of whom were accredited investors as that term is defined in Rule 501 of Regulation D under the Securities Act. All were capable of analyzing the merits and risks of their investment, acknowledged in writing that they were acquiring the securities for investment and not with a view toward distribution or resale, and understood the speculative nature of their investment. All securities issued contained a restrictive legend prohibiting transfer of the shares except in accordance with federal securities laws.

Item 3.

Defaults Upon Senior Securities

As of March 28, 2014 there are 5% Original Issue Discount Unsecured Convertible Debentures with a face value of $566,319 held by fifteen individual Holders in default. As a result, the outstanding principal amount of these Debentures, plus accrued but unpaid interest, liquidated damages and other amounts owing (estimated to be approximately $25,000) shall become immediately due and payable in cash at the election of the Holders. As of March 28, 2014, none of the Holders of these Debentures have elected to provide notice of default.

Item 4.

Mine Safety Disclosures

None

Item 5.

Other Information

None

Item 6.	Exhibits

10.1	Form of Subscription Agreement by and between the Company and Each Subscriber for the Company’s Convertible Debenture Offering.02.

10.2	Form of Debenture issued by the Company to each Subscriber in the Company’s Convertible Debenture Offering.

10.3	Form of Warrant issued by the Company to each Subscriber in the Company’s Convertible Debenture Offering.

31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*	Financial statements from the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2013, formatted in XBRL; (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statement of Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to the Consolidated Financial Statements.

* Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SpectraScience, Inc.
	(Registrant)

Date: March 28, 2014		/s/ Michael P. Oliver
		Michael P. Oliver
		President and Chief Executive Officer
		(Principal executive officer)

Date: March 28, 2014		/s/ Lowell W. Giffhorn
		Lowell W. Giffhorn
		Chief Financial Officer
		(Principal financial officer and principal accounting officer)